Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116394062 | 11639406 | 2 | F | 20160721 | 20151019 | 20160724 | PER | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-070346 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 137.00000 | KG | 20160724 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116394062 | 11639406 | 1 | PS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 20 MG, QD | 21436 | 20 | MG | TABLET | QD | ||||||
| 116394062 | 11639406 | 2 | SS | ABILIFY MAINTENA | ARIPIPRAZOLE | 1 | Intramuscular | 400 MG, QMO | 0 | 400 | MG | INJECTION | /month |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116394062 | 11639406 | 1 | Schizophrenia |
| 116394062 | 11639406 | 2 | Schizophrenia |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116394062 | 11639406 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 116394062 | 11639406 | 1 | 20151007 | 20151007 | 0 | |
| 116394062 | 11639406 | 2 | 20151007 | 20151009 | 0 |